, /PRNewswire/ -- (Nasdaq: ), (Nasdaq: ) (the "Company" or "Inspira"), a breakthrough medical technology company, announced today that the Company's President and co-founder, Mr. , presented a business plan with targets for the Company's next-generation technologies on a Company conference call today. On the call, Inspira unveiled plans to build an opportunity for a share of the mechanical ventilation market.
Inspira's mission is to eliminate the need for traditional mechanical ventilators, with its flagship the INSPIRATM ART (Gen 2) device, being designed to perform direct blood oxygenation, with the patient potentially being awake and without the need for intubation. Alongside the ongoing development of the INSPIRA ART (Gen 2) game-changing adaptive blood oxygenation technology, the Company is working on the multi-site deployment of the 510(k) U.S.
Food and Drug Administration (FDA) Cleared INSPIRA ART100, a cardiopulmonary support device. Under the existing distribution agreements with Glo-Med Networks, Inc, the Company has already received the first purchase order from the U.S.
distributor, with its first shipment scheduled for Q4 2024. InspiraTM Technologies is an innovative medical technology company in the life support arena. The INSPIRATM ART (Gen 2), also known as the INSPIRATM ART500, shall include the Company's Adaptive Blood Oxygenation technology and is being designed to continuously measure the patient's blood parameters in real-time, delivering needed oxygen vo.
